Trial Profile
A Phase 1 Open Label, Single Dose, Parallel-Group Study to Determine the Pharmacokinetics of Pacritinib in Patients With Impaired Hepatic Function in Comparison With Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary)
- Indications Myelofibrosis
- Focus Pharmacokinetics
- Sponsors CTI BioPharma
- 11 May 2016 New trial record